What is AP-472 used for?

AP-472 is indicated for Treatment-resistant depression.

AP-472 is developed by Appello Pharmaceuticals, Inc..

What are the side effects of AP-472?

Common side effects include Headache, Nausea, Dizziness.

Last reviewed 2026-04-23 · How we verify

AP-472

Appello Pharmaceuticals, Inc. · Phase 2 active Small molecule

AP-472 is a small molecule that targets the serotonin receptor 5-HT2A.

AP-472 is a small molecule that targets the serotonin receptor 5-HT2A. Used for Treatment-resistant depression.

At a glance

Generic name	AP-472
Sponsor	Appello Pharmaceuticals, Inc.
Drug class	Serotonin receptor antagonist
Target	5-HT2A
Modality	Small molecule
Therapeutic area	Psychiatry
Phase	Phase 2

Mechanism of action

By binding to the 5-HT2A receptor, AP-472 is thought to modulate the activity of this receptor, which is involved in various physiological processes including mood regulation and cognitive function.

Approved indications

Treatment-resistant depression

Common side effects

Headache
Nausea
Dizziness

Key clinical trials

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AP-472 CI brief — competitive landscape report
AP-472 updates RSS · CI watch RSS
Appello Pharmaceuticals, Inc. portfolio CI